


Supplementary Fig. S2. (A) Overall survival by number of prior lines of therapy. HR, 95% CI, and *P*-value are for line of therapy subgroups versus 0 line subgroup. (B) Overall survival by complex karyotype and del(17p) or complex karyotype without del(17p) in patients treated for relapsed/refractory CLL/SLL. HR, 95% CI, and *P*-value are for CK with del(17p) versus CK without del(17p). (C and D) Overall survival in patients with and without lymphocytosis at 1 year (C) and 2 years (D). HR, 95% CI, and *P*-value are for lymphocytosis at 1 year versus no lymphocytosis at 1 year (C) or lymphocytosis at 2 years versus no lymphocytosis at 2 years (D). (E) Overall survival from day 365 in patients who achieved a CR/PR or PR-L within the first 364 days on study. HR, 95% CI, and *P*-value are for CR/PR versus PR-L. (F) Overall survival by age. HR, 95% CI, and *P*-value are for age subgroups versus 0-50 years subgroup.

Overall survival time is calculated as the number of months from first dose date of study treatment to death or date of censoring. Tick marks represent censored patients.

CI, confidence interval; CR, complete response; HR, hazard ratio; NE, not estimable; NR, not reached; PR, partial response; PR-L, partial response with lymphocytosis.


A



0 line	31	27	27	26	26	26	26	26	25	25	23	20	20	20	17	9	2	0
1-2 lines	27	25	25	22	20	20	20	18	18	17	15	13	13	12	12	4	2	0
3 lines	14	14	12	10	10	9	9	9	9	9	8	8	7	5	4	0	0	
≥4 lines	60	51	48	43	38	32	31	25	24	23	20	19	17	12	10	6	1	0

	Median, months (95% CI)	7-year OS	HR (95% CI) P-value
0 lines of therapy (n=31)	NR (NE-NE)	84%	-
1-2 lines of therapy (n=27)	NR (63-NE)	67%	2.330 (0.681-7.966) P=0.177
3 lines of therapy (n=14)	NR (NE-NE)	85%	1.329 (0.243-7.262) P=0.743
≥4 lines of therapy (n=60)	70 (41-NE)	41%	5.709 (1.991-16.365) P=0.001


B



CK with del(17p)	22	20	18	16	13	11	8	7	5	4	4	4	3	3	3	2	2	2	0		
CK without del(17p)	15	15	14	12	12	12	10	10	10	9	8	5	5	5	5	4	4	4	4	1	0

	Median, months (95% CI)	7-year OS	HR (95% CI) <i>P</i> -value
CK with del(17p)(n=22)	32 (17-NE)	27%	2.548 (0.888-7.315) <i>P</i> =0.082
CK without del(17p)(n=15)	92 (25-NE)	61%	


C




Lymphocytosis at 1 year	54	54	54	50	48	46	45	41	40	38	35	32	31	27	24	15	3	0
No lymphocytosis at 1 year	78	63	58	51	46	41	41	37	36	36	32	28	27	24	20	8	2	0

	Median, months (95% CI)	7-year OS	HR (95% CI) <i>P</i> -value
Lymphocytosis at 1 year (n=54)	NR (92-NE)	71%	0.558 (0.295-1.056) <i>P</i> =0.073
No lymphocytosis at 1 year (n=78)	NR (66-NE)	54%	

D




E



CR/PR	75	72	68	66	61	61	57	56	53	49	48	43	42	38	34	20	11	1	0
PR-L	24	24	24	24	23	22	18	18	18	17	16	15	14	12	11	10	8	3	0

	Median, months (95% CI)	7-year OS	HR (95% CI) P-value
CR/PR (n=75)	NR (NE-NE)	71%	0.704 (0.316-1.569) P=0.391
PR-L (n=24)	NR (57-NE)	66%	

F



0-50 years	9	6	6	5	5	4	4	4	3	3	3	3	3	3	2	2	2	0			
>50-60 years	32	29	27	25	23	21	18	18	17	17	16	16	15	15	14	11	9	8	4	0	
>60-70 years	47	44	44	41	39	37	35	34	33	29	29	28	24	23	21	20	16	9	4	0	
>70-80 years	40	36	33	29	29	29	27	27	27	26	24	22	22	20	18	17	15	14	9	3	0
>80 years	4	3	3	3	3	3	3	3	3	3	3	3	3	3	2	2	2	1	0		

	Median, months (95% CI)	7-year OS	HR (95% CI) P-value
0-50 years (n=9)	70 (1-NE)	47%	—
>50-60 years (n=32)	NR (NE-NE)	73%	0.477 (0.123-1.845) P=0.284
>60-70 years (n=47)	92 (57-NE)	57%	0.751 (0.222-2.543) P=0.645
>70-80 years (n=40)	NR (66-NE)	65%	0.543 (0.151-1.952) P=0.350
>80 years (n=4)	NR (74-NE)	67%	0.428 (0.044-4.125) P=0.463